688089 Stock Overview
Develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cabio Biotech (Wuhan) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥26.03 |
| 52 Week High | CN¥30.12 |
| 52 Week Low | CN¥12.11 |
| Beta | 0.62 |
| 1 Month Change | 5.38% |
| 3 Month Change | 11.10% |
| 1 Year Change | 67.07% |
| 3 Year Change | 8.68% |
| 5 Year Change | -25.25% |
| Change since IPO | -21.07% |
Recent News & Updates
Recent updates
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Surges 26% Yet Its Low P/E Is No Reason For Excitement
Mar 07
Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) 26% Dip In Price Shows Sentiment Is Matching Earnings
Jan 12We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings
Nov 04Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively
Oct 28Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%
Oct 01There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump
Aug 06Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital
Jun 07Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
May 06Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations
May 03The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More
Mar 21Shareholder Returns
| 688089 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | 0.9% | -0.8% | -0.01% |
| 1Y | 67.1% | 1.2% | 10.1% |
Return vs Industry: 688089 exceeded the CN Chemicals industry which returned 1.7% over the past year.
Return vs Market: 688089 exceeded the CN Market which returned 11% over the past year.
Price Volatility
| 688089 volatility | |
|---|---|
| 688089 Average Weekly Movement | 10.4% |
| Chemicals Industry Average Movement | 6.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688089's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688089's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 565 | Dewei Yi | www.cabio.cn |
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.
Cabio Biotech (Wuhan) Co., Ltd. Fundamentals Summary
| 688089 fundamental statistics | |
|---|---|
| Market cap | CN¥4.38b |
| Earnings (TTM) | CN¥144.90m |
| Revenue (TTM) | CN¥594.54m |
Is 688089 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688089 income statement (TTM) | |
|---|---|
| Revenue | CN¥594.54m |
| Cost of Revenue | CN¥337.10m |
| Gross Profit | CN¥257.44m |
| Other Expenses | CN¥112.54m |
| Earnings | CN¥144.90m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 43.30% |
| Net Profit Margin | 24.37% |
| Debt/Equity Ratio | 3.2% |
How did 688089 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 04:47 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cabio Biotech (Wuhan) Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wendan Wang | China International Capital Corporation Limited |
| Yunpeng Fang | China International Capital Corporation Limited |
| Yifan Du | Citic Securities Co., Ltd. |